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Abstract. Laminin (laminin-1; a1-131-~/1) is known to 
promote myoblast proliferation, fusion, and myotube 
formation. Merosin (laminin-2 and -4; ¢x2-131/132-~/1) is 
the predominant laminin variant in skeletal muscle 
basement membranes; genetic defects affecting its 
structure or expression are the causes of some types of 
congenital muscular dystrophy. However, the precise 
nature of the functions of merosin in muscle remain un- 
known. We have developed an in vitro system that ex- 
ploits human RD and mouse C2C12 myoblastic cell 
lines and their clonal variants to study the roles of 
merosin and laminin in myogenesis. In the parental 
cells, which fuse efficiently to multinucleated myo- 
tubes, merosin expression is upregulated as a function 
of differentiation while laminin expression is downreg- 
ulated. Cells from fusion-deficient clones do not ex- 
press either protein, but laminin or merosin added to 
the culture medium induced their fusion. Clonal vari- 
ants which fuse, but form unstable myotubes, express 
laminin but not merosin. Exogenous merosin converted 
these myotubes to a stable phenotype, while laminin 
had no effect. Myotube instability was corrected most 
efficiently by transfection of the merosin-deficient cells 
with the merosin or2 chain cDNA. Finally, merosin ap- 
pears to promote myotube stability by preventing 
apoptosis. Hence, these studies identify novel biologi- 
cal functions for merosin in myoblast fusion and muscle 
cell survival; furthermore, these explain some of the 
pathogenic events observed in congenital muscular dys- 
trophy caused by merosin deficiency and provide in 
vitro models to further investigate the molecular mech- 
anisms of this disease. 
large part of our current understanding of the cellu- 
lar  and  molecular  mechanisms  involved  during 
myogenesis has been gained through the use of in 
vitro models (Weintraub et al., 1991; Edmondson and Ol- 
son, 1993; Weintraub, 1993). It is well established that the 
sequence of myoblast proliferation, myoblast fusion, and 
myotube formation, which characterizes the myogenic dif- 
ferentiation process, is regulated primarily by muscle-spe- 
cific transcription factors, such as MyoD, Myf-5, and myo- 
genin (Weintraub et al.,  1991; Olson,  1992; Edmondson 
and Olson, 1993; Weintraub, 1993; Lassar et al., 1994). It is 
also recognized that other types of molecules likewise play 
a pivotal role in the regulation of muscle differentiation; 
these include growth factors (Olson,  1992; Lassar et al., 
1994) as well as extracellular matrix (ECM) 1 components 
(Mayne and Sanderson, 1985; Engvall, 1993; Lassar et al., 
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1994)  and their cell surface receptors (Volk et al.,  1990; 
EngvaU, 1994; McDonald et al., 1995; Belkin et al.,  1996; 
Sastry et al., 1996). 
Laminins are a  family of basement membrane compo- 
nents that are composed of a heavy chain (c  0  and two sim- 
ilar but not identical light chains (13 and ",/) (Burgeson et al., 
1994; Wewer and Engvall, 1994). The "classical" laminin, 
laminin-1, is composed of the cd chain (400 kD) and the 
two 131/',/1 subunits (of ~205-220  kD). The predominant 
laminin variants in the muscle basement membrane con- 
tain the a2 heavy chain and are collectively referred to as 
merosin (Leivo and Engvall, 1988; Engvall, 1993; Wewer 
and Engvall, 1994). The tx2 chain is resolved as two frag- 
ments of 300 and 80 kD by electrophoresis under reducing 
conditions. In muscle basement membranes, this subunit 
associates predominantly with the 131/~1 chains as laminin-2, 
whereas it associates with the 132/'y1 chains as laminin-4 at 
neuromuscular junctions (Sanes et al.,  1990; Wewer and 
Engvall, 1994; Martin et al., 1995). 
Laminin-1 as well as fibronectin have been studied ex- 
tensively in myogenesis. Myogenic cell lines and myoblast 
primary cell cultures express both of these proteins (Kiihl 
et al., 1982; Mayne and Sanderson, 1985; Sanes et al., 1986; 
Kroll et al., 1994; Schuler and Sorokin, 1995). Laminin-1 is 
thought to play a prominent role in promoting myoblast 
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(Ktihl et al.,  1982; Foster et al.,  1987; Ocalan et al, 1988; 
Goodman et al.,  1989b;  von der Mark and t3calan, 1989; 
Kroll et al.,  1994)  whereas fibronectin, while stimulating 
myoblast  adhesion  and  proliferation, retards  or inhibits 
myogenic differentiation (Podelski et al., 1979; Foster et al., 
1987; vonder Mark and Ocalan, 1989).  Less is known of 
the function of merosin in myogenesis. Its expression ap- 
pears quite early during human and mouse muscle devel- 
opment in vivo (Sewry et al.,  1995; Schuler and Sorokin, 
1995) and the mRNA and protein for the tx2 and 132 chains 
have recently been found in cultured myoblasts (Martin 
et al., 1995; Schuler and Sorokin, 1995). The laminin-2 het- 
erotrimer is the predominant species synthesized by such 
cells  and  was  found  to  promote  faster  myoblast  cell 
spreading than laminin-1 (Schuler and Sorokin, 1995). 
Merosin is also implicated in muscle pathologies such as 
autosomal  recessive  congenital  muscular  dystrophies 
(CMD)  in humans  and in dy and dy  2J mice. Dystrophic 
symptoms in the dy  2J mouse  as well as in specific cases of 
CMD  are caused  by mutations in the  merosin a2 chain 
gene, which result in the synthesis of a truncated protein 
or of a complete absence of a protein (Hillaire et al., 1994; 
Sunada  et  al.,  1994,  1995;  Tom6 et  al.,  1994;  Xu  et  al., 
1994a,b; Hebling-Leclerc et al., 1995). This in turn can lead 
to severely defective muscle basement membranes (Xu et al., 
1994a). In some other cases of CMD, there is a reduction 
of merosin o~ or 13 chains as a result of mutations in genes 
which have not yet been identified (Hayashi et al.,  1993; 
Higuchi et al., 1994; Wewer et al., 1995). Because of the 
association  of merosin with  severe degenerative muscle 
diseases, the question of the precise roles of merosin in 
myogenic differentiation and skeletal muscle fiber mainte- 
nance is therefore an important one. 
In the present study, we have investigated the role of 
merosin in myogenic differentiation in vitro in comparison 
to that of laminin-1. Our data show that both proteins pro- 
mote myoblast fusion  and  myotube formation, but only 
merosin is essential for the stability and survival of myo- 
tubes. These results identify novel functions for merosin in 
muscle and provide key insight to the role of merosin-defi- 
ciency in the pathogenesis of CMD. 
Materials and Methods 
Myogenic Cell Lines and Cell Culture 
The  human  RD  rhabdomyosarcoma and  mouse  C2C12  myogenic cell 
lines were obtained from the American Type Culture Collection (Rock- 
ville, MD). Cells between passages 32 and 52 were maintained in DMEM 
(GIBCO BRL, Gaithersburg, MD) containing 10%  FBS (Hyclone, Lo- 
gan, Utah), 20 mM Hepes, 2% Eagle's non-essential amino acids solution 
(with glutamine; GIBCO BRL), 1 mM sodium pyruvate (GIBCO BRL) 
and antibiotics (growth medium), at 37°C in a humidified atmosphere of 
5%  CO2  in air.  Cultures were refed  every 48  h  and subcultured when 
~70-80%  confluent (-1  d postconfluence). Differentiation of cells  was 
initiated  at confluence (0 d postconfluence) by replacing the growth me- 
dium with complete DMEM but containing only 1% FBS (differentiation 
medium) and maintaining the cells  in this medium for 6 d  (Collo et al., 
1993; Katagiri et al., 1994; Kroll et al., 1994; Schuler and Sorokin, 1995). 
Inhibition of myogenic differentiation was achieved by adding to the dif- 
ferentiation  medium  human  recombinant  transforming growth  factor 
beta-1  (TGF-131; a generous gift from Dr. Daniel R. Twardzik), at the ef- 
fective  concentration of 10 ng/ml (Brunetti and Goldfine, 1990; Katagiri 
et al., 1994), or human recombinant basic fibroblast growth factor (bFGF) 
(GIBCO BRL), at the effective  concentration of 100 ng/ml (Brunetti and 
Goldfine, 1990). Growth and differentiation of cell cultures were routinely 
monitored by phase contrast microscopy. The degree of myogenic mor- 
phological differentiation was evaluated at each stage by scoring the num- 
ber of elongated bi- and multinucleated myotubes per mm  2 of culture sur- 
face (expressed as mean _+ SD), as described (Podelski  et al., 1979; Foster 
et al., 1987; Katagiri et al., 1994; Kroll et al., 1994). 
Myogenic Clonal Variant Cell Lines 
RD and C2C12 clonal variants were obtained by limiting dilution cloning 
from parental cells at passage 35. Subconfluent cultures were trypsinized 
according to standard procedures and single-cell  suspensions were plated 
at ~0.5  cells/8-mm  well  of 96-well  culture clusters (Costar Corp., Cam- 
bridge, MA), then grown for 10-15 d. For RD cells, clones from 18 wells 
were subcultured  and maintained,  and 15 of them were expanded (Table  1). 
For C2C12  cells, clones from 13 wells were subcultured and maintained, 
and 11 of them were expanded (Table I). Culture conditions of the clonal 
variants were as for the parental cell  lines.  In the present study, clonal 
variants were used between passages 5 and 15 after cloning; no changes in 
their behavior or in their expression of the proteins analyzed herein were 
observed. 
ExtraceUular Matrix Components (ECM) and ECM 
Protein-Overlay Cultures 
Laminin-1, merosin, and fibronectin were purified as previously described 
(Ehrig et  al.,  1990; Paulsson et  al.,  1991). Commercial preparations of 
laminin-1  and merosin (both from GIBCO BRL) were also used. Compo- 
sition and purity of preparations were evaluated by SDS-PAGE followed 
by Coomassie blue staining (see Fig. 2 B, lanes 3 and 4). The effects of 
these  ECM  components on  the  myogenic differentiation  properties of 
some clonal variants were analyzed according to the ECM protein-overlay 
method (Roskelley et al.,  1994). Briefly,  ceils were plated in 24-well cul- 
ture clusters (Coming, New York, NY) and, beginning at -  1 d postconflu- 
ence,  were  cultured  in  presence  of  0-100  /~g/ml of  either  laminin-1, 
merosin, fibronectin, or with a mixture of laminin-1  and merosin at equal 
concentrations, in growth medium (from -1 to 0 d postconfluence) or dif- 
ferentiation medium (from 0 to 6 d postconfluence). Medium with or with- 
out exogenous ECM components was renewed every 48 h  and cultures 
were scored  for myotube densities  by  phase  contrast microscopy (see 
above). 
Antibodies 
The following  monoclonal antibodies directed  to laminin subunits were 
used: 4C7, directed to the G domain of the human ctl chain (Engvall et al., 
1990); 4El0, directed to the human 131 chain (Engvall et al., 1990); 2E8, di- 
rected to the human 3'1 chain (Engvall et al., 1990); 5H2, directed to the G 
domain of the human a2 chain (Leivo and Engvall,  1988; Engvall et al., 
1990); and mAb 200, a rat monoclonal directed to the G domain of mouse 
cO chain (Sorokin et al., 1992; a gift from Dr. Peter Ekblom). Rabbit poly- 
clonal  antibodies used in the present study were: Ab 363, an antiserum 
that recognizes several laminin subunits of both human and mouse (Ehrig 
et al., 1990); Ab 804, an affinity-purified  antibody that recognizes the 80- 
kD fragment of the a2 chain of human and mouse merosin (Xu et al., 
1994a,b);  Ab 1301, an antiserum to a synthetic peptide derived from a se- 
quence of the second repeat in the G domain of the ct2 chain (Ehrig et al., 
1990; Paulsson et al., 1991), and which detects the 300-kD fragment of this 
chain (Xu et al., 1994a,b); Ab 1471, an affinity-purified  antiserum directed 
to the E3 fragment of laminin-1  (Paulsson et al., 1991); and anti-A2G, an 
affinity-purified  antiserum directed to a recombinant G domain of the a2 
chain (a gift from Dr. Peter D. Yurchenc). Antisera directed to skeletal 
muscle myosin heavy chain and to desmin (Sigma Chem. Co.,  St. Louis, 
MO) were also used. 
Indirect Immunofluorescence 
Immunofluorescence was performed on  cells  grown onto  13-mm  glass 
coverslips as  described  (Vach0n  and  Beaulieu,  1995). Rabbit  antisera 
were used  at  1:100  to  1:500  dilution,  affinity  purified antibodies were 
used at 10-30  ~xg/ml and hybridoma-conditioned media were used at 1 : 1 
to 1:5 dilution.  All dilutions were made in PBS  (pH 7.4) containing 2% 
BSA (Sigma).  FITC-conjugated goat anti-rabbit IgG, anti-mouse lgG, or 
anti-rat IgG (Boehringer Mannheim, Indianapolis, IN) were used as sec- 
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PBS, mounted in Vecta-Shield (Vector, Burlingame, CA) and viewed with 
an Axiovert 405M microscope (Carl Zeiss, Thornwood, NY) equipped for 
epifluorescence. Micrographs and histological counterparts were obtained 
as previously described (Beaulieu and Vachon, 1994).  In all cases, no im- 
munofluorescent staining was observed when primary antibodies were 
omitted or replaced by rabbit or mouse immunoglobins (not shown). 
RNA Purification and Reverse Transcription 
PCR (RT-PCR) 
Total RNA was isolated by the acid guanidinium thiocyanate-phenol-chlo- 
roform extraction method, as previously described (Xu et  al., 1994a,b). 
Cell cultures were washed three times with cold PBS before RNA extrac- 
tion. Reverse transcription and subsequent PCR was carried out with 1.0 
jxg of total RNA, as described elsewhere (Xu et al., 1994a,b). PCR prod- 
ucts (20 ILl out of a 60-~1 final reaction mixture) were resolved on 1.5% 
agarose  gels  stained  with  ethidium  bromide,  using  a  100-bp  ladder 
(GIBCO BRL) as standard. For the al chain of laminin-1, the following 
primers were used: the mouse-specific MA8243+ (5'-ACTTGGTGCTC- 
CCTCTGAATC-3')  and  MA9041-  (5'-ATGCGGTGCTTGCTqq'TG- 
TGG-3'), which amplify a 803-bp fragment (Sasaki et al., 1988);  and the 
human-specific HA1489+ (5'-GTGT'ffI'GTAAGGAAAACGTT-3') and 
HA2088-  (5'-TCAAAAGATGTGTCACATTG-3'), which generate  a 
600-bp  product  (Haaparanta  et  al.,  1991).  Primers  for  the ~t2 chain of 
merosin were: the mouse-specific MM191 +  (5'-AGTTGGTGGAACAT- 
GTCC-3') and MM802-  (5'-GTGTGACAATGGGATCGA-3'), which 
amplify a  610-bp  fragment (Xu  et  al.,  1994b);  and  the  human-specific 
HM6480+  (5'-TCAAAGTATCTGTGTCTTCAGGA-3') and HM6951- 
(5'-CCAGTGAATGTAATCACACGTACAGC-3'), which  generate  a 
470-bp product (Vuolteenaho et al., 1994). Primers for myogenin (Collo et 
al., 1993) and [3-actin (Stratagene, La Jolla, CA) were also used. 
35  S-Radiolabeling  and Immunoprecipitation 
Cells were washed with DMEM lacking methionine and cysteine (GIBCO 
BRL) and were incubated for 24 h  (37°C) in the same medium supple- 
mented with 1% FBS and 100 ~Ci/ml of Expre35S35S protein labeling mix 
(NEN-Dupont, Wilmington, DE). Radiolabeled or unlabeled conditioned 
media (24 h) from duplicate cell cultures at each stage studied were col- 
lected (5 ml/100-mm dish) and centrifuged (3,000 g, 10 min~ room temper- 
ature) to remove cell debris. One-fourth of fivefold concentrated immu- 
noprecipitation buffer (final concentration: 1% Triton X-100, 0.1% SDS, 
20 mM EDTA, 5 mM N-ethylmaleimide, 2 mM PMSF, 1 ~g/ml pepstatin, 
1 p~g/ml leupeptin, and 0.05% sodium azide in PBS, pH 7.4) was added to 
the media, followed by incubation (2 h, room temperature) with 1/20 vol- 
ume of gelatin-sepharose beads (Sigma) prewashed with immunoprecipi- 
ration  buffer,  to  remove  excess fibronectin.  Samples were  centrifuged 
again and the supernatants were aliquoted (1 ml) for storage (-70°C) un- 
til used. Immunoprecipitation of laminin molecules was performed as de- 
scribed previously (Leivo and Engvall, 1988; Engvall et al., 1990; Paulsson 
et al., 1991),  using protein A-coupled agarose beads (Sigma). Controls in- 
cluded  the  preimmune serum corresponding  to  each  rabbit  antiserum 
used or 2%  BSA-PBS (not shown). Immunoprecipitates were boiled (5 
rain,  105°C) in  l×  solubilization buffer (2.3%  SDS,  10%  glycerol, and 
0.001% bromophenol blue in 62.5 mM Tris-HC1 (pH 6.8) containing 5% 
13-mercaptoethanol), and samples were cleared by centrifugation (13,000 
rpm, 5 min, room temperature) before storage at -70°C until used. 
Gel Electrophoresis  and Immunoblotting 
SDS-PAGE was performed on 4-12% gels (NOVEX, San Diego, CA) as 
described  (Beaulieu and Vachon,  1994).  High  molecular mass markers 
(14.3-200 kD range; GIBCO BRL) were used as standards. Protein con- 
tents of all samples were estimated using the BioRad (Hercules, CA) pro- 
tein assay. Total protein (25-50 ~g/well) from radiolabeled immunopre- 
cipitates were separated, then gels were dried and exposed overnight at 
room temperature to X-Omat Kodak films. Total protein (25-50 p,g/well) 
from non-radiolabeled immunoprecipitates or from cell cultures solubi- 
lized in 1× solubilization buffer (Vachon and Beaulieu, 1995)  were sepa- 
rated  by  electrophoresis  and  then  electrotransfered  to  nitrocellulose 
membranes (Nitrocellulose-I; GIBCO BRL) for subsequent immunoblot- 
ting (Beaulieu and Vachon, 1994; Vachon and Beaulieu, 1995).  Affinity- 
purified antibodies were used at 5-10 Ixg/ml and antisera were used at 1: 
500-1 : 1,000 dilution. Immunoreactive bands were visualized using the en- 
hanced chemiluminescence method (ECL system; Amersham, Arlington 
Heights, 1L). 
In Situ Detection of Nuclear Condensation and 
Apoptosis-associated  DNA Strand Breaks 
Apoptotic nuclear condensation was visualized by staining cells cultured 
onto  13-ram cover slips with 4'-6-diamine-2'-phenylindole dihydrochlo- 
ride  (DAPI; Sigma) and counterstaining with Evans blue. Preparations 
were then mounted and viewed for epifluorescence. For in situ detection 
of apoptosis-associated DNA strand breaks, cover slip cell cultures were 
washed with PBS, fixed with 2% formaldehyde (Sigma) in PBS (45 rain, 
4°C) and quenched in 100 mM glycine-PBS (pH 7.4, 45 min, 4°C). Termi- 
nal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling 
(TUNEL) (Gavrieli et al., 1992) was then carried out using the ApopTag 
apoptosis detection kit (Oncor, Gaithersburg, MD) according to the man- 
ufacturer's  instructions, followed  by  counterstaining with  Evans  blue. 
Preparations were then mounted and viewed with a Zeiss LSM 410 confo- 
cal microscope. 
DNA Laddering Assays 
DNA was isolated from 100-mm cell cultures as described  (Frisch and 
Francis, 1994). DNA contents of all samples were estimated by OD2s~. For 
the  visualization of apoptosis-associated DNA  inter-nucleosomal frag- 
mentation (DNA laddering), each sample was then resolved by electro- 
phoresis (20 ~g DNA/lane) on 2% agarose gels stained with ethidium bro- 
mide, using a 100-bp DNA ladder (GIBCO BRL) as standard. 
Construction  of a Full-length  Human Merosin a2 
Chain cDNA 
A  DNA fragment containing nucleotides 13-268 of the a2 chain was 
amplified by PCR using Pfu DNA polymerase (Stratagene), the cDNA 
clone  M6-16  (Vuolteenaho et  al.,  1994)  as template and  the following 
primers:  5'-GTGTCTAGAqTTAAATTGGCTCCCGAGAAGGTGG- 
3'  and  5'-GACATGTTCTACCAATTTGC-3'.  An  overlapping  DNA 
fragment containing nucleotides 238-1081 was synthesized by PCR using 
the cDNA clone M5-1 (Vuolteenaho et al., 1994) as template and the fol- 
lowing  primers:  5'-TGAAATGTACTGCAAAqTGG-3'  and  5'-GGA- 
GTGCATGCq~FCACATTCAGTlq~AGTTAGAAAAGTTCCAGCTC 
TCCAGGG-3'. The two fragments were  then joined by strand-overlap 
PCR to generate a fragment containing nucleotides 13-1081 with an XbaI 
and a Swal restriction site immediately upstream of the translation initia- 
tion codon and extending to the SphI site at nucleotide 1080.  This frag- 
ment was sequenced to confirm that no mutations had been introduced by 
PCR. It was then inserted between the XbaI and SphI sites of the cDNA 
clone M10-22 (Vuolteenaho et al., 1994), a  3.2-kb fragment cloned into 
Bluescript II  (Stratagene),  therefore generating the plasmid p933.  The 
MscI/SacII fragment from clone MI-1 (Vuolteenaho el al., 1994), consist- 
ing of nucleotides 3940-6927, was in turn inserted between the MseI/SacII 
sites of p933. This gave the plasmid p936, containing nucleotides 13~5927. 
The BstBI/Pacl  fragment from the cDNA clone  MER3'  (Ehrig et  al., 
1990),  consisting of nucleotides 6510-9500, was subcloned in the BstBI/ 
PacI sites of pSL1190 (Pharmacia, Uppsala, Sweden) after first converting 
the Nrul site of pSL1190 to a PacI site by filling with the Klenow fragment 
of Escherichia  coli  DNA  polymerase  I  followed  by ligation  to  a  PacI 
linker. The eDNA fragment was then cut back out of this plasmid with 
BstBI and SacI1, then inserted between the BstBI/SacII sites of p936, thus 
generating the plasmid p937. This plasmid contains a unique SwaI site, fol- 
lowed by nucleotides 13-9500 of the full-length human et2 chain eDNA 
with a unique PaeI site at nucleotide 9500. 
A  vector for the expression of the full-length human a2 chain eDNA 
under  the  control  of  the  human cytomegalovirus promoter  was  con- 
structed as follows. First, the XbaI site of the expression vector pcDNA3 
(Invitrogen, San Diego, CA) was converted to a PacI site by filling with 
Klenow fragment of E. coil DNA polymerase I followed by ligation to a 
Pacl linker, thus giving the plasmid p938. Then, the full length SwaI/PacI 
eDNA fragment from p937 was inserted between the EcoRV/PacI sites of 
p938, finally giving the plasmid p941. To verify the capacity for expres- 
sion, COS-7 cells were transfected with p938 or p941  (see below)  and 
stained by immunofluorescence with monoclonal antibodies directed to 
the human merosin a2 chain. Intense cytoplasmic staining was observed in 
the COS-7/p941 cells, whereas no staining was evidenced in COS-7/p938 
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were renamed pc (control) and pmer (merosin) respectively, for simplicity. 
Stable Transfection of  Myogenic Cells 
Cell cultures at 50-60%  confluence were  transfected by the lipofection 
method (Lipofectamine; GIBCO BRL) according to the manufacturer's 
instructions with 10 txg of plasmid DNA. After the transfection, cells were 
kept in growth medium until 80-90% confluence, then split 1:5 and grown 
further for 2  d.  Thereafter, the growth medium was replaced  with  the 
same medium supplemented with 400 gg/ml of G418 sulfate (Geneticin; 
GIBCO BRL) for selection of stable transfectants. After 10-14 d, the sur- 
viving colonies were isolated by the cloning cylinder technique and ex- 
panded.  Transfected  cell  lines  were  thereafter  routinely  cultured  in 
growth or differentiation medium as for the non-transfected cell lines but 
in the continuous presence of the selection drug. Clones were used begin- 
ning at passage 4 after cloning. 
Results 
Myogenic Differentiation  of  RD and C2C12 Cells 
We first characterized the myogenic differentiation prop- 
erties  of the  human  RD  rhabdomyosarcoma and  mouse 
C2C12  myoblast cell lines.  Cultures  of growing RD cells 
typically consisted of small spindle-shaped and polygonal 
cells, while proliferating C2C12 cells exhibited a myoblast- 
like polygonal morphology (Fig. 1). Despite their cancer- 
ous origins, RD cells underwent extensive myoblast fusion 
and  myotube formation when  cultured  under  conditions 
that promote differentiation (CoUo et al., 1993; Katagiri et al., 
1994; Kroll et al., 1994), leading to an increase in the num- 
ber of myotubes within the first 6 d  of postconfluent cul- 
ture (Fig. 1; Table I). The cultures showed numerous elon- 
gated,  irregularly  arranged  multinucleated  myotubes  of 
various sizes and length (Fig. 1). C2C12 myotube densities 
also increased rapidly between 0  and 6  d  postconfluence 
under differentiation conditions,  the cultures exhibiting a 
large number of elongated, regularly arranged multinucle- 
ated myotubes of various sizes (Fig. 1; Table I). 
Merosin Expression Correlates with 
Myogenic Differentiation 
To ascertain  any potential function  for merosin in  myo- 
genesis, we analyzed its expression in relation to the myo- 
genic differentiation of both cell lines. RT-PCR was car- 
ried out on total RNA extracted from RD and C2C12 cell 
cultures at various stages to examine the time-course ap- 
pearance of merosin a2 chain mRNA (Fig. 2 A). For com- 
parison, the presence of the laminin c~1 chain and myoge- 
nin  mRNAs  were  analyzed  in  the  same  experiments. 
Expression of the  [3-actin  transcript was also  assessed to 
ensure cDNA integrity and amounts of cell-derived RNA 
as  starting  material  (Fig.  2  A).  In both  RD  and  C2C12 
cells,  the  levels  of  merosin  ct2  chain  mRNA  increased 
gradually  with  time  of postconfluent  culture  (Fig.  2  A). 
The laminin etl  transcript was barely detectable at  -1  d 
and  increased  after  1  d  postconfluence;  thereafter,  the 
levels  decreased  drastically  as  the  cells  completed  their 
myogenic differentiation (Fig. 2 A). The apparent gradual 
increase of the merosin a2 chain mRNA and the concomi- 
tant  decrease  of  the  laminin  ~1  chain  transcript  were 
found  concurrent  with  the  emergence  of the  myogenin 
mRNA (Fig.  2 A) and myotube formation (Table I). As 
expected from previous studies (Collo et al., 1993; Katagiri 
et al., 1994), myogenin mRNA was not detected in prolif- 
Figure  I.  Morphological 
characterization  of the myo- 
genic  differentiation  of  hu- 
man  and  mouse  myoblastic 
cells.  Representative  phase 
contrast micrographs of the 
human  RD  and  mouse 
C2C12 cells on culture  after 
-  1 d (undifferentiated)  or 6 d 
postconfluence  (differenti- 
ated).  Arrowheads  point  to 
myotubes. Bar, 50 Ixm. 
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Postconfluent (PC) Culture 
Number of myotubes/mm  z at  Number of myotubes/mm  2 at 
Type  Clone  -  1 PC  1 PC  6 PC  Clone  -  1 PC  1 PC  6 PC 
Parental  RD  0.2 -+ 0.1  1.5 + 0.2  9.0 ±  1.2  C2C12  0.0 ±  0.0  1.9 4- 0.7  13.2 ±  2.3 
1  RD.A4  0.2 ±  0.1  n.d.  8.7 ±  1.1  C2C12.A2  0.0 ±  0.0  n.d.  11.3  ±  3.2 
RD.B3  0.1  ±  0.1  1.0 +  0.1  7.4 ±  2.2  C2C12.B6  0.0 +  0.0  n.d.  12.5 -  1.2 
RD.C2  0.1  ±  0.1  1.0 ±  0.3  7.6 ±  1.3  C2C12.C9  0.0 ±  0.0  n.d.  12.7 ±  2.2 
RD.C6  0.2 ±  0.1  n.d.  9.0 -  2.4  C2C12.D2  0.0 +  0.0  2.1  ±  0.4  15.4 -  3.1 
RD.D1  0.1  ±  0.1  n,d.  8.2 +- 2.1  C2CI2.E2  0.0 ±  0.0  2.0 ±  0.7  14.3 +  2.2 
RD.E1  0.1  ±  0.1  1.0 ±  0.2  7.3 ±  1.5  C2C12F.9  0.0 ±  0.0  n.d.  16.4 ±  2.8 
RD.F5  0.1  ±  0.1  n.d.  7.5  ±  2.0  C2C12.H7  0.0 ±  0.0  1.0 +  0.3  13.0 ±  1.3 
RD.G4  0.1  ±  0.1  n.d,  8.5  ±  1.2 
2  RD.B8  0.1  ±  0.1  0.8 ±  0.1  0.5 ±  0.1"  C2C12.C1  0.0 ±  0.0  n.d.  1.9  ±  0.7 
RD.C3  0.1  ±  0.1  n.d.  0.3 ±  0.1"  C2C12.E6  0.0 ±  0.0  0.5  ±  0.1  2,1  ±  0.5 
RD.C4  2.2 ±  0.4  0.8 ±  0.2*  0.6 ±  0.1" 
RD.D6  0,1  ±  0.1  0.7 ±  0. l  0,3 ±  0.1" 
RD.HI  0.1  ±  0.1  n.d.  0.4 ±  0.2* 
3  RD.A9  0.0 ±  0.0  n.d.  0.0 ±  0.0  C2C12.B4  0.0 ±  0.0  0.0 ±  0.0  0.0 ±  0.0 
RD.D2  0.0 +- 0.0  0.0 ±  0.0  0.0 ±  0.0  C2C12.E5  0.0 ±  0.0  n.d.  0.0 ±  0.0 
Cells were cultured in growth medium (until 0-day postconfluence)  or differentiation  medium (from 0 to 6 d postconfluence).  At each culture stage, the number of myotubes/mm  2 
of culture surface was scored; values presented are mean ±  SD from three separate cultures (n/> 30). n.d., not determined. 
* Indicates evidence of extensive  myotube degeneration  and cell death. 
erating (undifferentiated) C2C12 ceils; rather, its expres- 
sion coincided with the onset of fusion and myotube for- 
mation in these cells (Fig. 2 A; Table I). 
The c~2 chain of merosin was also detected at the protein 
level. Analysis of 35S-radiolabeled proteins, immunopre- 
cipitated with a2 chain-specific antibodies, from the media 
of RD and C2C12 cell cultures indicated the presence of 
major polypeptides of 300, 205-220 and 80 kD after sepa- 
ration by SDS-PAGE under reducing conditions (Fig. 2 B, 
lanes 1 and 2). In agreement with previous reports (Kroll 
et al.,  1994; Schuler and Sorokin, 1995), these were found 
to correspond to the 300- and 80-kd segments of the a2 
chain of purified merosin (Fig. 2 B, lane 3) as well as to the 
common 205-220-kD 131 and ~1 subunits of both laminin-1 
and merosin (Fig. 2 B, lanes 3 and 4). By using immuno- 
blotting in time-course studies, we found that the amounts 
of c~2 chain increased gradually during myogenic differen- 
tiation of RD and C2C12 cells (Fig. 2 C), in a manner that 
paralleled that of the a2 chain mRNA (Fig. 2 A). This in- 
crease likewise followed that of myosin heavy chain and 
desmin (Fig. 2 C), the expression of which are known to be 
upregulated  as  a  function  of  myogenic  differentiation 
(Foster et al., 1987; Bandman, 1992; Katagiri et al., 1994). 
Laminin, as revealed in immunofluorescence by antise- 
rum  reactive with  multiple  subunits,  was  found  around 
myotubes as  well as in an  irregular network among un- 
fused myoblasts (Fig. 3 A). Intracellular staining was also 
observed. Detection for the  individual  [31  (Fig. 3  C), ~1 
(not shown), or cd (Fig. 3 E) chains revealed similar local- 
ization and staining patterns. However, the staining for the 
cxl chain at this terminal stage of differentiation was gen- 
erally weaker as compared to other subunits (Fig. 3 E), in 
agreement with the decrease in al chain mRNA observed 
in differentiated cultures (Fig. 2 A). The merosin a2 chain 
was found concentrated around myotubes (Fig. 3 G) and 
staining was generally much stronger than that for the al 
chain (compare Fig. 3, E and G). Hence, these results alto- 
gether show that the expression of merosin is upregulated 
as  myoblasts undergo myogenic differentiation, whereas 
that  of  laminin-1  is  downregulated.  Furthermore,  the 
merosin  heterotrimers synthesized by differentiated RD 
and C2C12 cells associate primarily with myotubes. 
Merosin Expression is Downregulated when Myogenic 
Differentiation is Inhibited 
To further investigate the correlation between the upreg- 
ulation of merosin and myogenic differentiation, as well as its 
inverse relationship with the downregulation of laminin-1, 
we analyzed the effects of TGF-[~I and bFGF on the ex- 
pression of the ~1  and e2 chains. The dose-dependent 
inhibitory action of these two growth factors on myogenic 
differentiation has  been well documented (Brunetti  and 
Goldfine, 1990; Olson, 1992; Katagiri et al., 1994; Lassar 
et al.,  1994).  The presence of 10 ng/ml of TGF-f31 or 100 
ng/ml of bFGF completely inhibited myoblast fusion and 
myotube formation (not shown). RT-PCR analysis of cells 
treated with either growth factor also revealed significant 
changes in laminin ed, merosin c~2, and myogenin mRNA 
levels (Fig. 4).  In  both TGF-[31 and bFGF-treated cells, 
the cd transcript was greatly increased. In contrast, treat- 
ment prevented the induction of merosin cx2 chain mRNA 
accumulation observed in untreated cultures. The myoge- 
nin  transcript  was  absent  in  growth  factor-treated cells 
whereas it was readily detectable in controls, as expected 
from previous reports (Brunetti and Goldfine, 1990;  O1- 
son, 1992; Katagiri et al., 1994). These results indicate that 
the  differential  expression  of  the  laminin  cd  and  the 
merosin e2 chains is a function of the myogenic differenti- 
ation program. 
Defective Myogenic Differentiation Is Correlated with 
Abnormal Laminin Expression 
We  sought  to  examine  whether  merosin  is  actually  re- 
quired  for  proper  differentiation.  For  this  purpose,  we 
generated clonal variants of RD and C2C12 cells by limit- 
Vachon et al. Role of Merosin in Myotube Formation and Stability  1487 Figure 2.  Molecular characterization  of the myogenic differentiation  of human and mouse myoblastic cells. (A) Expression of merosin 
a2, laminin al, myogenin, and ~-actin mRNA's during myogenic differentiation.  RT-PCR analyses of RD (lanes 1-3) and C2C12 (lanes 
4-6) cells after - 1 (lanes 1 and 4), 1 (lanes 2 and 5) and 6 d (lanes 3 and 6) of postconfluence.  The experiment shown is representative of 
three experiments.  L, 100-bp DNA size markers (DNA-ladder), the 600-bp marker being the most intense. (B) Representative immuno- 
precipitation and autoradiography of 35S-radiolabeled merosin synthesized by RD (lane 1) and C2C12 (lane 2) cells after 1 day of post- 
confluent  culture. For comparison, purified human merosin (lane 3) and mouse laminin-1 (lane 4) were separated on the same gels and 
stained with Coomassie blue. The cxl chain (400 kD), the 300- and 80-kD fragments of the ~2 chain  (et2300;  ~2s0), and the 131/'y1 chains 
(205-220 kD) are identified. Molecular masses are in thousands.  (C) Expression  of merosin during myogenic differentiation.  Immuno- 
blotting analysis of immunoprecipitated merosin c~2 chain synthesized by RD (lanes 1-3) and C2C12 (lanes 4--6) cells after -  1 (lanes 1 
and 4), 1 (lanes 2 and 5) and 6 d (lanes 3 and 6) of postconfluence,  using specific antibodies for the 300-kD (o~2300) and the 80-kD (c~280) 
fragments. Total protein from cell lysates were also probed with antibodies  specific for the myosin heavy chain (MHC; ~200 kD) and 
desmin (~,-55 kD). Immunoblot data shown are representative of three separate experiments. 
ing dilution cloning and assayed these for their myogenic 
differentiation  properties  and  for  the  expression  of the 
laminin and merosin ct chains. As summarized in Table I, 
the clonal variants generated could be classified into three 
general types. Type-1 RD and C2C12 clonal variants dis- 
played myogenic differentiation properties similar to their 
parental cell lines. These comprised the highest proportion 
of clonal variants obtained (t>53%), indicating a relatively 
good chromosomal stability  and  genetic homogeneity of 
the parental cell lines. Type-2 RD cell variants (5/15  of to- 
tal RD clones) also underwent fusion and myotube forma- 
tion, but the myotubes degenerated over the time-period 
studied  (6  d  postconfluence). This degeneration was evi- 
denced  by  the  appearance  of  cellular  blebs  protruding 
from myotubes and by the presence of dead cells at (and 
around) remaining phantom myotube-like structures (see 
Fig. 5 A, 7 B, and 8 B  for examples), resulting in signifi- 
cantly lower myotube densities  (Table I). Type-2 C2C12 
cell variants (2/11  of total C2C12 clones) proved to be fu- 
sion-ineffective  relative  to  the  parental  cells.  Finally, 
Type-3 RD (2/15 clones) and C2C12 (2/11  clones) variants 
were completely fusion-defective. 
We analyzed in some detail the properties of the RD.B8 
(Type-2), RD.D2 (Type-3) and C2C12.B4 (Type-3) clonal 
variants. The RD.B8 cells are able to fuse but show exten- 
sive myotube degeneration (or instability) after 6 d  post- 
confluence  (Fig.  5  A).  Differentiated  cell  cultures  con- 
tained  high  levels  of  the  ed  chain  mRNA  but  lacked 
detectable a2 chain mRNA and protein (Fig. 5 B, and C), 
unlike the parental RD cells. The RD.D2 cells, which do 
not undergo  myoblast fusion  (Fig.  5 A),  did  not  contain 
detectable al or a2 chain mRNA (Fig. 5 B).  Lack of ex- 
pression of both chains was also noted in the fusion-defec- 
tive C2C12.B4 cells (Fig. 5 A-C). To ensure that the be- 
havior of these variants was not caused by a  deficiency 
in myogenic regulatory factors, each was assayed for the 
expression of myogenin which lies downstream of the hier- 
archy of regulatory proteins that drive the myogenic dif- 
ferentiation program (Weintraub et al., 1991; Olson, 1992; 
Edmondson  and  Olson,  1993;  Lassar  et  al.,  1994)  and 
which is required for myoblast fusion to occur (Weintraub, 
1993;  Lassar et al.,  1994).  As shown in Fig.  5  B, each of 
these three clonal cell lines were positive for the myogenin 
transcript.  These data show that  myotube instability can 
be associated with merosin deficiency, while  fusion-defi- 
ciency can be correlated to a  lack of expression of both 
laminin-1 and merosin. 
Roles of  Laminin-1 and Merosin in Myotube Formation 
and Stability 
We then  analyzed directly the  function  of laminin-1  and 
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laminin and merosin subunits 
in  differentiated  myogenic 
cell cultures by immunofluo- 
rescence. Representative  mi- 
crographs of RD cells at 6 d 
postconfluence after fixation, 
permeabilization  and  stain- 
ing for multiple laminin sub- 
units (A), the  [31 chain (C), 
the  al  chain (E),  or the  a2 
chain  (G),  with human  spe- 
cific polyclonal (A) or mono- 
clonal  (C,  E,  G) antibodies. 
(B, D, F, H) Corresponding 
histological  counterparts  to 
(A, C, E, G). Arrows point to 
a single myotube. Bar, 25 Ixm. 
merosin in myogenic differentiation, using the differentia- 
tion-defective RD.B8, RD.D2, and C2C12.B4 cells. Cultur- 
ing the myotube-unstable RD.B8 cells (Fig.  6 A) with ei- 
ther laminin-1 or fibronectin as ECM protein-overlays had 
no effect on the stability of the myotubes formed, regard- 
less  of the concentration used.  In contrast, a  clear dose- 
dependent effect of merosin on RD.B8 myotube stability 
was observed, which was reflected by increased myotube 
densities. Addition of both laminin-1 and merosin at equal 
concentrations resulted in similar dose-dependent effects 
on myotube stability, but not significantly different from 
that  exhibited  by merosin  alone,  therefore  indicating  a 
merosin-specific influence  on myotube stability.  It is  of 
note that merosin, alone or in combination with laminin-1, 
almost  completely  rescued  the  unstable  myotubes  in 
RD.B8 cells: myotube densities formed under these condi- 
tions were ~0.5 times those found in cultures of the paren- 
tal RD ceils  (for example, 4.6 myotubes/mm  2, in the pres- 
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genic  differentiation  by 
TGF-131  and  bFGF  affect 
laminin et chains and myoge- 
nin  expression  in  C2C12 
cells.  RT-PCR  analyses  of 
laminin cd, merosin c~2, myo- 
genin,  and  8-actin  mRNA 
levels after 6 days of postcon- 
fluent culture  without  added 
growth  factors  (lane  1)  or 
with  10  ng/ml  of  TGF-131 
(lane  2)  or  100  ng/ml  of 
bFGF (lane  3).  The  experi- 
ment shown is representative 
of  three  separate  experi- 
ments. 
ence of 100 tzg/ml merosin, versus 9.0 for the parental cells 
at the same culture stage; Fig. 6 A  and Table I). 
Both  laminin-1  and  merosin  induced  myotube forma- 
tion  in  a  dose-dependent  manner in the  fusion-defective 
RD.D2 (Fig. 6 B) and C2C12.B4  (Fig. 6  C) cells. In con- 
trast, fibronectin had no effect as expected (Podelski et al., 
1979; Foster et al., 1987; von der Mark and Ocalan, 1989). 
Using laminin-1  and  merosin  together  induced  myotube 
formation at a lower protein concentration than either one 
alone and yielded more myotubes (about twofold). More- 
over, there was no evidence of myotube degeneration and 
cell death, whereas these were evidenced when laminin-1 
was used alone. Hence, these results suggest a synergistic 
effect by laminin-1  and merosin on myogenesis, and fur- 
ther support a specific role for merosin in myotube stability. 
Rescue of  Differentiation-defective  Myoblasts by 
Transfection with a Full-length Human Merosin ce2 
Chain cDNA 
To confirm the roles of merosin in myotube formation and 
stability, we transfected some of the differentiation-defec- 
tive, merosin-negative cell lines with an expression vector 
(pmer)  containing  a  full-length  cDNA  encoding  the  hu- 
man c~2 chain, under the regulation of the human cytomeg- 
alovirus promoter.  The  expression  vector without  insert 
(pc) was used as control in parallel experiments. RT-PCR 
analysis of selected clones showed the presence of the hu- 
man tx2 chain mRNA in  the pmer-transfected but not in 
control-transfected  cells  (not  shown).  Immunofluores- 
cence using monoclonal  anti-human  c~2 chain  antibodies 
revealed the expression of the merosin protein and its as- 
sociation with myotubes, indicating proper assembly of the 
human c~2 chain with the endogenous 13 and "y chains (Fig. 
7A). 
The  parental  C2C12  cells  transfected  with  the  human 
merosin c~2 chain exhibited a  1.5-fold increase in their ca- 
pacity to form myotubes (Table II). In contrast,  control- 
transfected C2C12  cells showed no notable difference in 
their differentiation properties, as compared to non-trans- 
fected cells (Tables I  and II). The C2C12.B4 variant cells 
were then stably transfected with the pmer vector, in an at- 
tempt  to  rescue  their  fusion-defective  phenotype.  As 
shown above, these cells express neither the cd nor the c~2 
chains,  but do express the  131/~/1 chains  (not  shown)  and 
can  be induced  to  form myotubes by adding  exogenous 
laminin-1, merosin, or both (see Fig. 6 C). The C2C12.B4/ 
pmer  transfectants  underwent  fusion  and  myotube  for- 
mation (Fig. 7 B; Table II) nearly as efficiently as the pa- 
rental  C2C12  cells.  Furthermore,  the  transfection  of the 
merosin a2  chain  cDNA  was  more  efficient  in  rescuing 
C2C12.B4 ceils than the addition of high concentrations of 
purified merosin, or of an equal mixture of laminin-1 and 
merosin as protein-overlays (see Fig. 6 C). In contrast, the 
C2C12.B4/pc controls remained fusion-defective (Fig. 7 B; 
Table II). These findings confirm a capacity of merosin to 
support and promote myoblast fusion. 
The  a2  chain  transfection  also  corrected  the  myotube 
instability in the RD.B8 cells (Fig. 7 B; Table II), fully re- 
storing the phenotype of the parental RD cells. Transfec- 
tion  with  the  control  vector  had  no  effect.  Again,  the 
transfection with merosin a2 chain was significantly more 
efficient in restoring myotube stability than the addition of 
merosin to the culture medium (see Fig. 6 A). These ob- 
servations confirm a  role  for merosin  in  promoting and 
maintaining the stability of myotubes. 
Unstable, Merosin-deficient Myotubes 
Undergo Apoptosis 
To gain additional insights into the mechanisms by which 
merosin promotes myotube stability, we tested the hypoth- 
esis that the degeneration of myotubes in the ct2 chain-defi- 
cient RD.B8 cells was linked to apoptosis. Numerous dead 
cells  at  (and  around)  degenerating  myotubes  were  ob- 
served  in  differentiated  RD.B8  cell  cultures;  these  cells 
were shrunken  and rounded,  and became detached from 
the plates or were only loosely adherent (Fig. 5 A), typical 
of apoptotic cells. Staining with the DNA-binding fluoro- 
chrome  DAPI  revealed  chromatin  condensation  and 
shrunken,  compact  nuclei  in  degenerating  myotubes  as 
early as 3 d postconfluence (not shown). This was not ob- 
served in unfused myoblasts. Probing for the presence of 
DNA  strand  breaks  using  the  TUNEL  method  showed 
strong  incorporation  of labeled  nucleotides  in  nuclei  of 
myotubes that had not yet begun to degenerate (Fig. 8 B), 
whereas weak to strong labeling was also noted  in  myo- 
tubes already advanced in their degeneration process (Fig. 
8 B), indicating that apoptosis precedes the myotube de- 
generation in these cells. Unfused myoblasts did not incor- 
porate  labeled  nucleotides  (Fig.  8  B).  Apoptosis-associ- 
ated  inter-nucleosomal  fragmentation  (DNA  laddering) 
was also evident as early as 3 d  postconfluence in RD.B8 
cells (Fig. 9, lane 2), and this DNA fragmentation was in- 
creased with time after confluence (Fig. 9, lane 3), consis- 
tent with an increased number of apoptotic cells.  In con- 
trast,  no  evidence  of  myotube  degeneration  (Fig.  1), 
incorporation of labeled nucleotides  (Fig.  8 A), or DNA 
laddering  (Fig.  9,  lane  I) were observed in  parental  RD 
cells at the same stages. 
Finally,  the  restoration  of  c~2  chain  expression  in  the 
transfected  RD.B8/pmer  cells  corrected  their  phenotype 
of myotube instability and consequently abolished the ac- 
cumulation of apoptotic cells in cultures (Fig. 7 B) and in- 
hibited  apoptosis-associated DNA fragmentation  (Fig.  9, 
lane 5). In contrast, dead cells (Fig. 7 B) and DNA ladder- 
ing (Fig. 9, lane 4) were observed consistently in control- 
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tiation-defective  cell  lines. 
Clonal  variants  of  RD  and 
C2C12  cells  were generated 
by  dilution  limiting  cloning 
and evaluated for their myo- 
genic differentiation  proper- 
ties.  Shown  here  in  A  are 
representative phase contrast 
micrographs of 6 d postcon- 
fluent RD.B8 cells, which ex- 
hibit  extensive  myotube  in- 
stability  and  degeneration 
(arrows  point  to  degenerat- 
ing myotubes, which are sur- 
rounded  by dead cells);  and 
RD.D2 and  C2C12.B4  ceils, 
which  are  fusion-defective. 
(B) Laminin al, merosin ct2, 
myogenin, and  [3-actin gene 
expression  as  detected  by 
RT-PCR in 6 d postconfluent 
RD (lane I), RD.B8 (lane 2), 
RD.D2 (lane 3), C2C12 (lane 
4)  and  C2C12.B4  (lane  5) 
cells. The experiment shown 
is  representative  of  three 
separate  experiments.  (C) 
Immunofluorescence  micro- 
graphs  of 6  d  postconfluent 
RD.B8  and C2C12.B4  cells 
after  fixation,  permeabiliza- 
tion and staining for the de- 
tection  of  the  laminin  al 
chain  or  the  merosin  a2 
chain,  with  specific  mono- 
clonal  antibodies.  Arrows 
point  to  a  single  myotube. 
Bars: (A) 50 ~m; (C) 25 ~m. 
transfected  RD.B8/pc  cells.  Therefore,  these  data  alto- 
gether  indicate  that  merosin  promotes  myotube stability 
by preventing apoptosis. 
Discussion 
The  myogenic differentiation  process  is  essentially  com- 
prised of three distinct stages: myoblast proliferation, myo- 
blast fusion into myotubes, and myotube stabilization and 
survival. In the present study, we have examined the roles 
of merosin and laminin-1 in this process, particularly in the 
two latter stages. We found that merosin expression is up- 
regulated  as a function of myogenic differentiation,  while 
laminin-1  expression  undergoes  simultaneous  downregu- 
lation.  Our  results  also provide  clear evidence  that  both 
proteins  can  promote  myoblast fusion  and myotube for- 
mation, but only merosin promotes the structural stability 
as well as the survival of myotubes. Accordingly, a lack of 
merosin and laminin expression  precludes fusion in myo- 
blasts even in the presence of the muscle regulatory factor 
myogenin,  whereas  a  lack  of merosin  expression  causes 
myotube  apoptosis,  instability  and  degeneration.  Hence, 
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Figure 6.  Effects of merosin and laminin on myotube formation 
and stability. The RD.B8 (A), RD.D2 (B) and C2C12.B4 (C) cells 
were cultured in the presence of extracellular matrix protein- 
overlays consisting of 13-100 Ixg/ml  of purified merosin (open cir- 
cles), laminin-1 (filled circles), an equal mixture of merosin and 
laminin-1 (filled squares), or fibronectin  (open squares), begin- 
ning at -1 d postconfluence  (under growth conditions)  and up to 
6 d postconfluence  (under differentiation  conditions),  at which 
time  the  numbers  of myotubes/mm  2 of culture  surface  were 
scored. Values presented are mean + SD from three separate ex- 
periments (n t> 15). A star indicates evidence of extensive myo- 
tube degeneration and cell death. 
these  findings  indicate  that  both  molecules  are  crucial 
players in the myogenic differentiation process. 
Merosin and Laminin-1 Are Expressed as Part of the 
Myogenic Differentiation Program 
Myogenesis is primarily driven by a fine-tuned program of 
gene regulation which causes the withdrawal of myoblasts 
from the cell cycle and leads to the emergence of the ter- 
minally differentiated,  multinucleated,  post-mitotic myo- 
tubes  (Weintraub  et  al.,  1991;  Olson,  1992;  Edmondson 
and  Olson,  1993;  Weintraub,  1993;  Lassar  et  al.,  1994). 
Several lines of evidence now suggest that the differential 
expression of laminin-1 and merosin in differentiating myo- 
blasts constitutes  an  integral  part of this program. First, 
the two molecules are expressed according to a develop- 
mental  sequence  where  laminin-1  preceeds  the  onset  of 
myogenesis  (Ktihl  et  al.,  1982;  Mayne  and  Sanderson, 
1985;  Sanes  et al.,  1986;  Foster et  al.,  1987;  Klein et  al., 
1990;  Kroll et al.,  1994),  while merosin is associated with 
differentiated  myofibers (this  study;  Leivo and  Engvall, 
1988; Ehrig et al., 1990; Schuler and Sorokin, 1995; Sewry 
et al., 1995). Second, we found that the expression of the 
muscle regulatory factor myogenin is  directly correlated 
with that of merosin and inversely correlated with that of 
laminin-1. Third, TGF-131  and bFGF upregulated the ex- 
pression of laminin-1 and downregulated that of merosin, 
while  also  inhibiting  myogenin expression,  myoblast fu- 
sion,  and  myotube  formation.  Finally,  fibroblasts  trans- 
fected with MyoD, another muscle regulatory transcription 
factor,  undergo  myogenic  differentiation  and  concomi- 
tantly acquire the ability to express laminin-1, as well as a 
350-kD polypeptide that could be the a2 chain of merosin 
(Kroll et al.,  1994).  These observations also suggest a di- 
rect action of muscle regulatory factors on the differential 
regulation of the expression of laminin-1 and merosin dur- 
ing muscle development. 
Merosin and Laminin-1 Perform Shared as Well as 
Unique Roles in Myogenesis 
Our use of differentiation-defective myogenic clonal vari- 
ant cell lines have provided new evidence on the functions 
of laminin-1 and merosin in myogenic differentiation. The 
precise  causes  of  the  defective  properties  exhibited  by 
these cells are unknown  and likely to be complex. How- 
ever,  that  the  correction  of  their  phenotypes  could  be 
achieved by the addition of either laminin-1 or merosin as 
ECM protein-overlays, or by transfection with the merosin 
c~2 chain cDNA,  indicates  that the  lack of expression of 
laminin  cd  and/or  merosin  a2  chains  observed  in  these 
variants were in fact the critical defects. 
The present study, along with others which have focused 
on  the  role  of  laminin-1  in  myogenesis,  indicate  that 
merosin and laminin-1 play both similar and distinct roles 
at specific stages of the myogenic differentiation process: 
laminin-1 promotes myoblast proliferation, both proteins 
promote fusion, but only merosin promotes myotube sta- 
bility. A  specific role for laminin-1 in myoblast prolifera- 
tion is supported by the demonstration that it acts as a po- 
tent promoter of this process in vitro (Foster et al., 1987; 
(3calan et al., 1988; Goodman et al., 1989b;  yon der Mark 
and (3calan,  1989)  and by the observations that it is the 
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of  myogenic  differentiation- 
defective cells with a full length 
human  a2  chain  cDNA.  Se- 
lected  clones  stably transfected 
with  either  pc,  the  expression 
vector without any insert  (con- 
trol),  or  pmer,  the  expression 
vector containing the full-length 
human  a2  chain  cDNA  under 
regulation  of  the  human  cyto- 
megalovirus  promoter.  (A) 
Clones of transfected cells were 
cultured  under  differentiation 
conditions until  6 d  postconflu- 
ence,  fixed,  permeabilized  and 
then stained for the a2 chain of 
human  merosin  with  a  human- 
specific  monoclonal  antibody. 
Representative  clones  of  the 
C2C12.B4  and  RD.B8 cells  are 
shown.  Arrows point to a single 
myotube.  (B)  Morphology  of 
C2C12.B4  and  RD.B8  trans- 
fected  cells.  Arrows  point  to 
multinucleated,  stable  myo- 
tubes or to degenerating, unsta- 
ble  myotubes  which  are  sur- 
rounded by dead cells. Bars: (A) 
25 Ixm; (B) 50 txm. 
predominant  laminin  molecule  expressed  until  myoblast 
fusion is initiated  (this study; Ktihl et al., 1982; Mayne and 
Sanderson,  1985;  Sanes  et  al.,  1986;  Foster  et  al.,  1987; 
Klein et al., 1990; Kroll et al., 1994). Furthermore, laminin-1 
expression is a common feature of proliferating myoblasts 
(KUhl  et  al.,  1982; Sanes et  al.,  1986; Foster  et  al.,  1987; 
Kroll et al., 1994) and regenerating muscle fibers (Hayashi 
et al., 1993; Tom6 et al., 1994; Xu et al., 1994a). Although 
it  remains  possible  that  merosin  shares  with  laminin-1  a 
role in the proliferation of myoblasts, the fact that it is ex- 
pressed  later  than  laminin-1  and  coincident  with  fusion 
and myotube formation (this  study; Schuler and Sorokin, 
1995; Sewry et al., 1995) implies that its primary role is dif- 
ferent. 
Our  data  do  indicate  that  both  proteins  can  perform 
similar functions in myogenesis, specifically in the promo- 
tion of myoblast fusion. A role for laminin-1 in this process 
has been suggested previously (Ktihl et al., 1982; Foster et 
al.,  1987;  vonder  Mark  and  121calan,  1988;  Volk  et  al., 
1990), but such a function for merosin is demonstrated for 
the first time here. That these two molecules are capable 
of exerting similar  activities  is  not surprising,  considering 
the similarities  in their structural  and functional domains 
(Leivo and Engvall, 1988; Ehrig et al., 1990; Paulsson et al., 
1991; Vuolteenaho et al., 1994; Wewer and Engvall, 1994). 
Accordingly,  myoblasts  adhere  equally  well  to  them 
(Schuler and Sorokin,  1995) and both proteins have been 
shown to perform similar functions in other biological pro- 
Vachon et al. Role of Merosin in Myotube Formation and Stability  1493 Table II. Effects of Stable Transfection with a Full-length 
Human Merosin 0~2 Chain cDNA on Myotube Formation and 
Stability 
No. of clones  Myotubes! 
Transfectant*  selected  mm  2 at 6 PC*  Myotube degeneration  ~ 
C2Cl2/pc  15  13.6 _  2.6  no (15/15) 
C2Cl2//pmer  30  21.5 _+ 2.4  no (30/30) 
C2CI2.B4/pc  15  0.0 +_ 0.0  n.a.  [r 
C2C12.B4/pmer  20  8.0 +  1.3  no (20/20) 
RD.B8/pc  10  0.5 _  0.2  yes (10/10) 
RD.B8/pmer  20  9.7 -  1.2  no (20/20) 
*Cells  were stably transfected with either pc, the expression vector without insert 
(control), or pmer, consisting of the expression vector containing the full-length hu- 
man merosin a2 chain cDNA under the regulation of the human cytomegalovirus pro- 
moter, Selected clones were cultured in growth medium (until 0-d postconfluence) or 
differentiation medium (from 0 to 6 d postconfluence), in the presence of 400 p~g/ml 
G418 sulfate. 
::The number of myotubes/mm  2 of culture surface was scored at 6 d PC for each clone 
analyzed. Values presented are mean +- SD from three separate cultures (n/> 50). PC, 
postconfluence. 
~Evidence (yes) or absence (no) of extensive myotube degeneration and cell death af- 
ter 6 d postconfluence.  Parentheses indicate the number of clones scored positive or 
negative over the total number of clones analyzed. 
ILn.a., not applicable. 
cesses,  such  as  in  the  promotion  of neurite  outgrowth 
(Engvall et al., 1992). However, the biological relevance of 
the functional overlap between merosin and laminin-1 in 
myoblast fusion remains  unclear.  Our  observations  that 
the laminin- and merosin-deficient RD.D2 and C2C12.B4 
cells fail to undergo fusion, whereas the laminin-express- 
ing but merosin-deficient RD.B8 cells do fuse, suggest that 
merosin may not be necessary for fusion while laminin-1 
would be required. This is further supported by the fact 
that muscle fiber development apparently occurs normally 
in merosin-deficient cases of CMD  (Hayashi et al., 1993; 
Tom6 et al., 1994), as well as in the dystrophic dy and dy  2J 
mice (Sunada et al., 1994, 1995; Xu et al., 1994a,b). On the 
other hand, myoblasts lose their adhesion and responsive- 
ness  to  laminin-1  just  prior to  fusion  (Goodman et  al., 
1989a), a change in cell behavior which may occur in re- 
sponse to the  emergence of merosin (this  study)  and  to 
concomitant changes in the expression of cell surface re- 
ceptors (Volk et al.,  1990; Collo et al., 1993; Song et al., 
1993; McDonald et al., 1995; Zhidkova et al., 1995; Belkin 
et al., 1996). Our protein-overlay assays further indicated a 
potential synergy of merosin and laminin-1 in myoblast fu- 
sion. Such synergy could possibly optimize fusion events 
and thus potentiate myotube formation during myogenesis 
in vivo. That myofibers are consistently smaller at birth in 
merosin-deficient cases  of  CMD  (Hayashi  et  al.,  1993; 
Tom6 et al.,  1994; Campbell, 1995) seems to support this. 
Therefore, further analysis of the respective contributions 
of laminin-1 and merosin in the fusion process will be re- 
quired  in  order  to  resolve  the  inconsistencies  between 
these observations. 
A  specificity of function for merosin in myogenic cellu- 
lar processes has been inferred by the fact that it is the pre- 
dominant laminin variant in basement membranes of de- 
veloping and mature muscle fibers (Leivo and Engvall, 1988; 
Engvall,  1993;  Schuler and  Sorokin,  1995;  Sewry et  al., 
1995). This assumption is further supported by the recent 
observations that myoblasts display faster cell spreading 
on  laminin-2  than  on  laminin-1  (Schuler  and  Sorokin, 
1995) and that merosin can exert functions in other tissues 
that are distinct from that of laminin-1, such as in the case 
of the differential modulation of brush border membrane 
hydrolase  expression  in  intestinal  epithelial  absorptive 
cells (Beaulieu and Vachon, 1994; Vachon and Beaulieu, 
1995). Herein, our results clearly established that merosin 
is essential for the stabilization of myotubes, whereas lami- 
nin-1 does not exert any effect on this process. Hence, this 
indicates that merosin performs a unique function in the 
promotion and maintenance of the structural integrity of 
myofibers. This novel, but critical, role of merosin partly 
explains  the  progressive  deterioration  of  muscle  fibers 
seen  in  CMD  with  merosin  deficiency (Hayashi  et  al., 
1993;  Sunada  et  al.,  1995;  Tom6 et  al.,  1994;  Xu  et  al., 
1994a,b;  Hebling-Leclerc et  al.,  1995),  which  leads  ulti- 
mately to severe histological abnormalities and degenera- 
tion. 
That merosin and laminin-1 perform shared and distinct 
functions at specific stages of myogenesis raise the ques- 
tion of the cell surface receptors involved. Integrins  are 
recognized as the principal mediators of ECM-cell interac- 
tions  and  signaling  (Hynes,  1992;  Ruoslahti  and  Reed, 
1994; Roskelley et al., 1995), and their importance in myo- 
genesis has been demonstrated in Drosophilia,  C. elegans 
and avians (Volk et al., 1990; Engvall, 1994; Lassar et al., 
1994; McDonald et al., 1995; Sastry et al., 1996).  In mam- 
malian muscle, the e~71M integrin is regarded as the primary 
laminin-binding receptor (Collo et al.,  1993;  Song et al., 
1993; Echtermeyer et al., 1996) and splicing variant forms 
of its two subunits are expressed differentially as a func- 
tion of myogenic differentiation (Collo et al., 1993; Song 
et  al.,  1993;  Zhidkova et  al.,  1995;  Belkin  et  al.,  1996). 
Hence, the et7BI31A complex is found in proliferating/un- 
differentiated myoblasts but is gradually replaced by the 
c~7AI31D variant integrin as cells undergo fusion and myo- 
tube formation (Collo et al., 1993; Song et al., 1993; Zhid- 
kova et al.,  1995; Belkin et al,,  1996).  Such a  switch ap- 
pears strongly coincidental with the differential expression 
and stage-specific roles of laminin-1 and merosin described 
here. It is therefore likely that these variant integrins are 
mainly responsible for the mediation of the functions ex- 
erted by merosin and laminin-1 during the myogenic dif- 
ferentiation process. 
Role of Merosin Deficiency in the Pathogenesis of CMD 
Several of the muscular dystrophies characterized so far 
may be regarded as diseases of muscle cell adhesion and 
are caused by mutations in a number of proteins that link 
the cytoskeleton of the cell to the ECM  (Engvall, 1994; 
Tinsley et al.,  1994; Campbell,  1995),  thus disrupting the 
cytoarchitecture  of  myofibers  as  well  as  compromising 
their binding to the basement membrane. There is accu- 
mulating evidence that the deterioration of myofibers seen 
in these diseases results from an increase in programmed 
cell  death  (Lockshin  et  al.,  1995;  Matsuda  et  al.,  1995; 
Smith et al.,  1995; Tidball et al.,  1995).  This may be ex- 
pected, considering the  importance of the  ECM  for the 
survival of cells in vitro and  the demonstration that the 
disruption of cell attachment induces apoptosis (Meredith 
et al., 1993; Frisch and Francis, 1994; Ruoslahti and Reed, 
1994; Boudreau et al., 1995).  In this context, the correla- 
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by  merosin-deficient  myo- 
blasts  undergo  apoptosis. 
Representative double stain- 
ing immunofluorescence mi- 
crographs of 3 d postconflu- 
ent  cultures of the parental, 
myotube-stable RD cells (A) 
and  the  myotube  unstable, 
merosin-deficient  RD.B8 cells 
(B)  after  in  situ  dioxigenin- 
conjugated dUTP labeling of 
apoptosis-associated  DNA 
strand breaks by the TUNEL 
method, followed by incuba- 
tion with an FITC-conjugated 
anti-dioxigenin  antibody 
(green)  and  counterstaining 
with  Evans  blue  (red).  Ar- 
rows point  to a  single  myo- 
tube (A and B); arrowheads 
point to a degenerated myo- 
tube  (B); and  asterisks  indi- 
cate  unfused  myoblasts  (A 
and B). Bar, 10 Ixm. 
tion between increased apoptosis and lack of merosin ex- 
pression as revealed in the present study, in addition to the 
observation that extensive apoptosis does occur in dy and 
dy  zJ muscle in vivo and in primary cultures (Vachon, P.H., 
and  E.  Engvall,  unpublished  observation),  strongly  sup- 
port the concept that merosin deficiency in CMD results in 
undue apoptosis in muscle fibers, thus leading to their de- 
generation and subsequent necrosis. 
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correlated  with  apoptosis  in 
myogenic cells. DNA (20 Ixg/ 
lane)  was  isolated  from  3 
(lane 2) or 6  d  (lanes 1, 3-5) 
postconfluent  RD  (lane  1), 
RD.B8  (lanes  2-3),  RD.B8/ 
pc (lane 4) and RD.B8/pmer 
(lane 5) cell cultures, and as- 
sayed  for evidence  of apop- 
tosis-associated  internucleo- 
somal  DNA  fragmentation 
(DNA laddering).  L,  100-bp 
DNA size markers. 
The mechanisms involved in merosin-mediated survival 
of muscle cells remain unknown at this time. For instance, 
myotubes  underwent  rapid  and  massive  degeneration  in 
our merosin-deficient in vitro models, whereas such accel- 
erated pace of the degenerative process of diseased muscle 
fibers  clearly  does  not occur in vivo.  In fact,  CMD  with 
merosin  deficiency  is  a  relatively  slowly progressing  dis- 
ease.  This  points to the  existence  of multiple  compensa- 
tory factors  which  may  include continuous regeneration, 
other ECM components, and growth factors derived from 
myoblasts and/or other cell types in muscle tissues (Lock- 
shin et al.,  1995).  As  an example,  the insulin-like growth 
factor II (IGF-II) was recently shown to inhibit muscle cell 
apoptosis in the dystrophin-deficient mdx mouse (Smith et 
al.,  1995). Therefore,  the identification of trophic factors 
that can functionally synergize with merosin in the preven- 
tion of apoptosis  may provide  a  better  understanding of 
myofiber survival in vivo. 
In conclusion, the present findings provide key insight 
into the distinct roles of merosin and laminin-1 in myogen- 
esis and CMD caused by merosin deficiency, and identify 
novel functions of merosin  in myoblast fusion, myofiber 
stability, and muscle cell survival. The in vitro model sys- 
tems featured here will be useful for delineating the signal- 
ing pathways underlying these  and for further  dissecting 
the molecular bases of muscle development and disease, as 
well as investigating potential treatments.  In this respect, 
the  rescue  of  the  differentiation-defective  RD.B8  and 
C2C12.B4 cells by transfection with a full-length merosin 
a2  chain  cDNA  shows  promise  in  the  development  of 
therapeutic  strategies  involving myoblast  transplantation 
coupled to gene therapy for the treatment of merosin-defi- 
cient CMD. 
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